Preclinical pharmacokinetic, biodistribution, radiation dosimetry, and toxicity studies of 99mTc-HYNIC-(Ser)3-LTVPWY: A novel HER2-targeted peptide radiotracer

Ardakani, Javad Biabani; Amiri, Fereshteh Talebpour; Khorramimoghaddam, Alireza; Abbasi, Ali; Molavipordanjani, Sajjad; Hosseinimehr, Seyed Jalal

doi:10.1016/j.yrtph.2020.104591

Cited by 6 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the peptides that displayed bold characteristics as a radiotracer for HER2 imaging is a peptide with the sequence Leu-Thr-Val-Pro-Trp-Tyr (LTVPWY). The reports suggest that 99m Tc-radiolabeled derivatives of LTVPWY ( 99m Tc-HYNIC-(Ser) 3 -LTVPWY) not only bind to HER2 overexpressing ovarian tumor xenografts but also successfully visualize GBM xenografts [6,15,16]. Moreover, DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)-conjugated LTVSPWY is also evaluated for ovarian tumor xenografts with the overexpression of HER2 receptor after radiolabeling with 68 -Galium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraaceticacid-Ser-Ser-Ser-Leu-Thr-Val-Ser-Pro-Trp-Tyr ( 68 Ga-DOTA-(Ser)3-LTVSPWY) [17].…”

Section: Introductionmentioning

confidence: 99%

Initial preclinical evaluation of 68Ga-DOTA-(Ser)3-LTVSPWY peptide as a PET radiotracer for glioblastoma targeting and imaging

Ranjbar

Molavipordanjani

Ardakani

et al. 2022

Nuclear Medicine Communications

Self Cite

View full text Add to dashboard Cite

Purpose Imaging of glioblastoma multiform (GBM) tumor using 68-Galium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraaceticacid-Ser-Ser-Ser-Leu-Thr-Val-Ser-Pro-Trp-Tyr (68Ga-DOTA-(Ser)3-LTVSPWY) as a PET radiotracer for HER2 receptor due to fact that this receptor plays a pivotal role in the tumorigenesis and tumor progression in a wide range of cancer. Methods 68Ga-DOTA-(Ser)3-LTVSPWY was produced with high radiochemical purity. The affinity and specificity of this radiotracer toward HER2 receptor on the surface of glioma glioblastoma (U-87 MG) cell line were evaluated. Furthermore, the biodistribution and PET imaging of this radiolabeled peptide were investigated on xenografted U-87 MG tumor-bearing mice. Results The in-vitro specific binding study revealed that the 68Ga-DOTA-(Ser)3-LTVSPWY binds to different cell lines with respect to their level of HER2 expression. The calculated KD and Bmax of radiolabeled peptide toward U-87 MG cell line were 5.5 ± 2.4 nmol/l and (2.4 ± 0.3) × 105 receptors per cell, respectively. The highest tumor uptake was observed at 30-min postinjection, whereas the tumor-to-muscle ratio was about four-fold. The acquired PET images distinctively show tumor site, which was blocked with excess nonlabeled peptide that revealed specific in-vivo targeting of 68Ga-DOTA-(Ser)3-LTVSPWY for glioma. Conclusion 68Ga-DOTA-(Ser)3-LTVSPWY specifically recognizes HER2 receptors and could be a potential candidate for GBM imaging.

show abstract